Patients initially received two cycles of neoadjuvant docetaxel ( 100 mg/m ( 2 ) intravenously every 3 weeks ) plus trastuzumab ( 8 mg/kg intravenously every 3 weeks then 6 mg/kg intravenously every 3 weeks for the second course ) .